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CASE REPORT

Signs of Psychosis Leading to a Diagnosis of Progressive
Multifocal Leukoencephalopathy: A Case Report
Bryan L. Walker, MD,1 Christina Holt, MD, MSc1
1
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Introduction:

Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating process of the central
nervous system that occurs in patients who are severely immunocompromised. Patients with PML
develop varying focal neurological deficits and mental status changes that have not been welldescribed.

Clinical findings:

We present a patient who was found wandering the lobby of this hospital by security. He was oriented
only to self and unable to state a reason for presentation. Medical records were limited and included
a visit to an outside hospital that documented a past medical history of human immunodeficiency
virus (HIV) infection. He exhibited multiple signs of psychosis, such as thought blocking and a
disorganized thought process.

Diagnoses,
Interventions,
and Outcomes:

After thorough evaluation, he was diagnosed with HIV-associated PML based on a CD4 count of 68
cells/µL, signal abnormalities in subcortical white matter on brain MRI, and positive cerebrospinal
fluid polymerase chain reaction (PCR) for JC virus (JCV). Despite initiation of antiretroviral therapy
(ART), the patient clinically declined and was ultimately transitioned to hospice care.

Conclusions:

While survival from PML has significantly improved with the advent of ART, the overall prognosis
remains poor. This case report emphasizes that PML should be included in the differential diagnosis
for immunocompromised patients with mental status changes, even if they do not present with overt
focal neurological deficits. It also highlights the importance of continuous medical care for HIV to
minimize the risk of patients developing such devastating complications.

Keywords:

progressive multifocal leukoencephalopathy, HIV, AIDS, opportunistic infections, psychotic disorders

A

39-year-old male was found wandering the
lobby of this hospital by security personnel.
He appeared confused and was escorted to
the emergency department. He was oriented only to
self and unable to state a reason for presentation.
His medical records revealed sparse, episodic care.
In 2016, he was seen at an outside hospital that
documented a history of human immunodeficiency
virus (HIV) infection with last use of antiretroviral
therapy (ART) one year prior.
In the emergency department, he was unable to
follow instructions for a complete physical exam.
Limited neurological exams were still performed
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and generally documented as “nonfocal,”
suggesting no easily perceptible muscle weakness,
speech abnormality, or gait disturbance was
present. However, several physicians noted that he
exhibited multiple signs of psychosis, including a
disorganized thought process, abrupt interruptions
in speech consistent with thought blocking (e.g.,
patient stated “I just need you to…” and then would
stop talking), apparent responses to internal stimuli
(e.g., during an interview, patient suddenly pointed
into space and said, “really want something else”),
and nonsensical answers to providers’ questions
(e.g., when asked if he had friends or family, patient
responded, “other things to go - supposed to be. I’m
already tracing everything”).
Head computed tomography (CT) showed patchy
areas of hypodensity within subcortical white
1
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matter (Figure 1A, B). HIV-1 antibody was positive.
CD4 count was 68 cells/µL (reference range 577–
1623). Brain magnetic resonance imaging (MRI)
showed areas of signal abnormality in subcortical
white matter concerning for progressive multifocal
leukoencephalopathy (PML) (Figure 1C, D).
Polymerase chain reaction studies of cerebrospinal
fluid were positive for JC virus, confirming
the diagnosis of PML. ART was initiated with
emtricitabine-tenofovir alafenamide (200–25 mg
daily) and dolutegravir (50 mg daily).
The patient’s clinical course was complicated by
intermittent refusal of care, several attempts to elope
from the unit, and marked behavioral dysregulation
requiring antipsychotic therapy. Unfortunately, no
personal contacts could be identified after extensive
outreach attempts. Emergency guardianship was
granted to the state. Despite treatment, his clinical
condition declined with loss of mobility, dysphagia,
and seizures. Given his progressive course and
poor prognosis, care was transitioned to comfort
measures and he was discharged with hospice
services.

DISCUSSION
Progressive multifocal leukoencephalopathy is
a demyelinating process of the central nervous
system that was first described in 1958.1 It is
caused by the JCV, which is estimated to lie
dormant in 39–91% of the world’s population.2
The virus is reactivated in the setting of severe
immunocompromise due to either an underlying
disorder (e.g., HIV) or immunomodulatory therapies
(e.g., natalizumab, rituximab).3 The vast majority of
patients with HIV infection who develop PML have
CD4-positive T-cell counts < 200 per mm.3 Thus, the
Centers for Disease Control and Prevention (CDC)
classified PML as an acquired immunodeficiency
syndrome (AIDS)–defining opportunistic illness
(OI).4 In patients with at least one AIDS-defining
OI, only 1.0% present with PML as the first OI to
occur, making PML a rare initial complication of HIV
infections.5
Patients with PML typically develop focal
neurological deficits, depending on the specific
brain regions affected by the demyelination. Thus,
presenting symptoms can vary widely between
patients and include hemiparesis, ataxia, aphasia,
hemianopsia, and mental status changes.6 The
precise characteristics of mental status changes
are not well described in the literature. Most studies
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have typically grouped together patients exhibiting
confusion, dementia, or obtundation, and then
simply reported the total as a percentage of patients
with altered mentation or cognitive dysfunction.6,7
While such patients may have shared certain initial
clinical features with the patient we present, the
exact cognitive abnormalities they demonstrated
remains unclear. Additionally, there are only a few
case reports that highlight atypical presentations
of PML, such as with HIV-associated dementia.8
To our knowledge, this case report is the first to
thoroughly describe a patient with HIV-associated
PML presenting to medical care with signs of
psychosis.
To date, there are no specific targeted treatments
for PML. The main approach to treatment is
restoring the patient’s immune system with
effective ART to allow for normal host response to
the JCV.9 Prior to the advent of effective ART in the
mid-1990s, the one-year survival rate of patients
with HIV-associated PML was just 10%.6 Now,
initiation of effective ART significantly improves
survival rates.10–13 In one study, the median survival
time increased from 0.4 to 1.8 years in patients
diagnosed with PML after 1997.13 The authors note
that while survival has significantly improved, the
overall prognosis for patients with PML remains
poor, with a high mortality rate and high degree of
neurological sequelae among survivors.
Unfortunately, this patient had previously received
outpatient HIV treatment only briefly and was
subsequently lost to follow-up. He was one of the
hundreds of thousands of patients across the country
who are not receiving ART through continuous HIV
medical care. Recent surveillance data from the
CDC shows that of the 794,145 teenage and adult
patients with HIV infection in the United States,
only 57.2% were retained in HIV care.14 In a large,
population-based study in the United States, nearly
half of all cases of the most common serious OI,
Pneumocystis carinii pneumonia, occurred in
persons not receiving medical care.15 Effective ART
significantly protects against the development of
all OIs, and since its introduction, the incidence of
these diseases has declined precipitously in the
US.15–19 Increased efforts are urgently needed to
implement and develop effective interventions to
help patients establish and remain in HIV care.20
Without such ongoing care, patients will remain
susceptible to devastating complications, as seen
in this case report.
2
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Figure 1. Neuroimaging
Panel A, B: Non-contrast axial CT head images showing patchy areas of hypodensity within the
subcortical white matter of the bilateral temporal and anterolateral frontal lobes.
Panel C, D: Axial T2-weighted FLAIR MR images demonstrating confluent signal abnormalities in the
subcortical white matter corresponding to the lesions identified on the CT.
CT, computed tomography; MR, magnetic resonance; FLAIR, fluid-attenuated inversion recovery
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